Business Update Positive

2026-08-26 16:44

- Board approved the voluntary liquidation of Bharat Serums and Vaccines Limited (BSVL), a material wholly-owned subsidiary (96% direct, 4% indirect). - BSVL's business will be consolidated with Mankind Pharma on a going concern basis. - The move aims to drive operational efficiency, consolidate business, improve cash management, and rationalize expenses.

Business Update Positive

2026-08-26 16:40

- Board approved the initiation of voluntary liquidation process for Bharat Serums and Vaccines Limited (BSVL), a material wholly-owned subsidiary. - BSVL's business will be consolidated with Mankind Pharma on a going concern basis. - This strategic move aims to drive operational efficiency, effective resource utilization, improved organizational execution, cash management, and enhanced governance. - Appian Properties Private Limited, holding 4% of BSVL, will receive cash proportionate to its shareholding.

Business Update Positive

2026-08-22 14:00

- Mankind Pharma's ESG Rating improved to 64, categorized as "Strong," from the previous rating of 57 ("Adequate"). - The Company's Core ESG Rating also improved to 71 from 60. - The rating was independently assigned by CRISIL ESG Ratings & Analytics Limited based on FY2026 disclosures.

Business Update Positive

2026-08-20 13:37

- Mankind Pharma entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, on August 20, 2026. - The agreement is for commercialization of Insulin Degludec and Insulin Degludec + Aspart Combination in India. - This strengthens Mankind's presence in the diabetes segment and expands its injectable portfolio.

Governance Neutral

2026-08-18 15:50

- Mankind Pharma Limited issued a Postal Ballot Notice for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for five consecutive years from August 10, 2026. - The e-voting period is from August 19, 2026 (9:00 AM IST) to September 17, 2026 (5:00 PM IST). - Results will be declared on or before September 21, 2026.

Ownership Positive

2026-08-17 23:08

- Mankind Pharma Limited has completed the realignment of the security cover for its Non-Convertible Debentures (NCDs). - As a result, 28,280 pledged equity shares of Bharat Serums and Vaccines Limited (BSVL), constituting 38.68% of BSVL's paid-up equity capital, have been released. - The revised security cover for the NCDs is now 1.26 times the outstanding amount, with no BSVL shares remaining under pledge.

Business Update Positive

2026-08-13 21:31

- Mankind Pharma Limited announced the incorporation of its wholly-owned subsidiary, "Mankind Pharma (Netherlands) B.V.", in the Netherlands on August 13, 2026.

Governance Neutral

2026-08-10 16:25

- Board of Directors meeting held on August 10, 2026. - Approved the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director, effective August 10, 2026. - His appointment is for a term of 5 consecutive years, subject to members' approval via postal ballot.

Governance Positive

2026-08-10 16:23

- The Board of Directors approved the appointment of Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. This appointment is for a term of 5 (five) consecutive years, subject to the approval of the members via a Postal Ballot. Mr. Bafna has over 30 years of experience in the healthcare and medical devices sector.

Governance Positive

2026-08-10 16:12

- Mankind Pharma Limited appointed Mr. Anish Vanraj Bafna as an Additional Director, designated as a Non-Executive Independent Director, effective August 10, 2026. This appointment is for a term of 5 consecutive years, subject to shareholder approval via Postal Ballot. Mr. Bafna brings over 30 years of experience in the healthcare and medical devices sector.

Business Update Neutral

2026-08-10 12:40

- Investor Conference Schedule - August 13, 2026: Emkay Confluence (Mumbai) - One-on-One / Group Meeting - August 13, 2026: Equirus Annual India Conference '26 (Mumbai) - One-on-One / Group Meeting - August 17, 2026: Motilal Oswal 22nd Annual Global Investor Conference, 2026 (Mumbai) - One-on-One / Group Meeting - No unpublished price sensitive information will be disclosed during these meetings.

Governance Positive

2026-08-06 16:01

- Mankind Pharma Limited's 35th AGM held on August 4, 2026. - All four resolutions, including adoption of financial statements, re-appointment of directors Mr. Rajeev Juneja and Mr. Satish Kumar Sharma, and ratification of cost auditors' remuneration for FY 2026-27, were approved with requisite majority.

Governance Neutral

2026-08-04 17:38

- Mankind Pharma Limited's 35th Annual General Meeting (AGM) was held on August 4, 2026, via video conferencing. - Key items included adopting FY2025-26 financial statements (standalone and consolidated), re-appointing directors, and ratifying cost auditor remuneration. - Auditors' reports had no qualifications or observations.

Business Update Positive

2026-08-04 13:26

- Maintained FY27 double-digit growth guidance for overall business, with Chronic business expected to perform better and Acute business to recover. - Maintained FY27 EBITDA margin guidance of 25.5% to 26.5%. - Gross margin guidance upward of 71% for FY27, taking a conservative approach due to potential commodity price increases and West Asia crisis impacts. - On track to repay acquisition-related debt by FY28, with net debt to adjusted EBITDA ratio at 0.9x in Q1 FY27. - Aims to increase chronic portfolio share to 50% in the medium term from the current 40%. - Consumer Healthcare business expected to achieve high single-digit to double-digit growth from Q2 FY27 onwards. - BSV business expected to deliver high double-digit growth (high teens) for FY27.

Routine Neutral

2026-07-30 20:33

New Filing detected. See link for details.

Financials Negative

2026-07-30 16:01

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05Cr vs ₹2,569.73Cr (▲15.34% YoY) - EBITDA ₹928.58Cr vs ₹684.93Cr (▲35.57% YoY) - PAT ₹558.49Cr vs ₹415.27Cr (▲34.49% YoY) - EBITDA Margin 31.32% vs 26.65% (▲467bps)

Financials Positive

2026-07-30 15:55

- Consolidated Revenue ₹4,031 Cr vs ₹3,570 Cr (▲12.9% YoY) - EBITDA ₹1,060 Cr vs ₹850 Cr (▲24.7% YoY) - PAT ₹574 Cr vs ₹445 Cr (▲29.1% YoY) - EBITDA Margin 26.3% vs 23.8% (▲250bps)

Financials Positive

2026-07-30 15:42

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.34% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.57% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.49% YoY) - Standalone EBITDA Margin 31.39% vs 26.65% (▲474bps) - Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. - Approved issuance of a corporate guarantee in favour of Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary. - Noted ongoing income tax proceedings initiated against the company for which appeals are pending; management believes its position is tenable. - Disclosed the acquisition of the Branded Generic Business of BSV (Women's Health Portfolio) for ₹797 Cr, effective November 1, 2025, resulting in restatement of prior year figures. - Approved the divestment of 100% stake in Broadway Hospitality Services Private Limited for ₹49 Cr and the incorporation of a new subsidiary in Netherlands for R&D.

Financials Neutral

2026-07-30 15:31

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹4,030.59 Cr vs ₹3,570.35 Cr (▲13% YoY) - EBITDA ₹1,105.13 Cr vs ₹929.82 Cr (▲19% YoY) - PAT ₹574.09 Cr vs ₹444.62 Cr (▲29% YoY) - EBITDA Margin 27.4% vs 26.0% (▲138bps) - Board approved a corporate guarantee of ₹150 Cr for its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSV). - The Company divested its 100% stake in Broadway Hospitality Services Private Limited for ₹49 Cr. - Auditors highlighted ongoing income tax proceedings from FY23-24 with assessment orders making adjustments of ₹1,908.66 Cr, currently under appeal. - Exceptional items include an impairment loss of ₹13.44 Cr related to a greenfield project in Hyderabad.

Financials Positive

2026-07-30 15:24

CRITICAL RED FLAG DETECTED

- Standalone Revenue ₹2,964.05 Cr vs ₹2,569.73 Cr (▲15.3% YoY) - Standalone EBITDA ₹928.58 Cr vs ₹684.93 Cr (▲35.6% YoY) - Standalone PAT ₹558.49 Cr vs ₹415.27 Cr (▲34.5% YoY) - Standalone EBITDA Margin 31.4% vs 26.7% (▲470bps)

Business Update Neutral

2026-07-27 18:16

- Mankind Pharma Limited has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited. - The Share Purchase Agreement was executed on July 27, 2026. - The sale was for a cash consideration of ₹49 Crore, subject to closing adjustments.

Business Update Neutral

2026-07-17 15:40

- Concall Schedule - Concall Date: Thursday, 30th July 2026 - Concall Time: 06:30 PM - 07:30 PM IST - Call Details: https://us06web.zoom.us/webinar/register/WN_gjCF6TrYR9eK24zP-RYSZQ

Financials Neutral

2026-07-16 16:34

- A Board Meeting will be held on Thursday, July 30, 2026. - To consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. - The trading window for trading in securities will remain closed till August 1, 2026.

Business Update Positive

2026-07-11 13:33

- The Board approved the divestment of 100% stake held in Broadway Hospitality Services Private Limited, a wholly-owned subsidiary, for a consideration of ₹49.00 Crores. - The Board also approved the incorporation of a wholly-owned subsidiary in Netherlands to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies, with a proposed investment of up to Euro 5 Million.

Business Update Positive

2026-07-11 13:29

- Board of Directors approved the divestment of 100% stake in Broadway Hospitality Services Private Limited for ₹49.00 Crores. - Approved the incorporation of a wholly-owned subsidiary in Netherlands with an investment of up to Euro 5 Million. - The WOS will focus on R&D assets and business development activities for niche therapies.

Business Update Positive

2026-07-11 13:24

- The Board of Directors approved the divestment of 100% stake in Broadway Hospitality Services Private Limited for a consideration of ₹49.00 Crores. - The Board also approved the incorporation of a Wholly Owned Subsidiary in the Netherlands with a proposed investment of up to Euro 5 Million, to hold R&D assets and pursue business development activities in niche therapies.

Business Update Neutral

2026-07-09 17:05

- Filing of the Business Responsibility & Sustainability Report (BRSR) for Financial Year 2025-26 as per Regulation 34(2)(f). - The report outlines the company's approach to sustainability, ethical conduct, and stakeholder engagement. - For FY 2025-26, the company reported a turnover of ₹10,421.18 Cr and a net worth of ₹16,396.94 Cr.

Governance Neutral

2026-07-09 16:57

- Mankind Pharma Limited's 35th Annual General Meeting (AGM) for FY 2025-26 will be held on Tuesday, August 4, 2026, at 03:30 P.M. (IST) via VC/OAVM. - Key agenda items include adopting financial statements, re-appointing directors Mr. Rajeev Juneja and Mr. Satish Kumar Sharma, and ratifying cost auditors' remuneration. - Remote e-voting runs from August 1, 2026, to August 3, 2026, with July 29, 2026, as the cut-off date.

Governance Neutral

2026-07-09 16:48

- Mankind Pharma Limited announced its 35th Annual General Meeting (AGM) for the financial year 2025-26. - The AGM will be held on Tuesday, August 4, 2026, at 3:30 P.M. (IST) via Video Conferencing/OAVM. - Agenda includes adoption of financial statements, reappointment of directors Mr. Rajeev Juneja and Mr. Satish Kumar Sharma, and ratification of cost auditors for FY2026-27. - Remote e-voting will be available from August 1, 2026, to August 3, 2026.

Governance Neutral

2026-07-09 16:36

- Notice for the 35th Annual General Meeting (AGM) for FY2025-26 to be held on Tuesday, August 4, 2026, at 3:30 P.M. (IST) via Video Conferencing/OAVM. - Remote e-voting period: Saturday, August 1, 2026 (9:00 A.M. IST) to Monday, August 3, 2026 (5:00 P.M. IST). - Cut-off date for determining eligible members for voting is Wednesday, July 29, 2026. - Agenda includes adoption of financial statements, re-appointment of Directors, and ratification of Cost Auditors' remuneration.

Governance Neutral

2026-06-30 12:01

- The 35th Annual General Meeting (AGM) of Mankind Pharma Limited is scheduled for Tuesday, August 4, 2026, at 03:30 p.m. (IST). - The meeting will be held through Video Conferencing/Other Audio-Visual Means. - The Notice of AGM along with the Annual Report for the financial year 2025-26 will be dispatched.

Routine Neutral

2026-06-25 12:25

- Trading window closed from July 01, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. - The Board Meeting date for results will be intimated in due course.

Business Update Neutral

2026-06-15 15:42

- Investor Conference Participation - Event: IIFL's Invest India Conference & Capital Day 2026 - Dates: June 23, 2026 & June 24, 2026 - Location: London - Meeting Type: One on One and Group Meeting

Governance Neutral

2026-06-08 22:24

- Mankind Pharma appointed Mr. Nilesh Kulkarni as Head of Human Resource Functions and designated him as a Senior Management Personnel (SMP) effective June 8, 2026. - This is part of an internal organizational restructuring and strategic realignment of the HR leadership framework. - Mr. Prateek Dubey ceased to be an SMP and will transition to new roles and responsibilities within the company.

Ownership Neutral

2026-06-08 18:18

- Allotment of 86,778 equity shares on June 8, 2026, under the ESOP Plan 2022. - Paid-up share capital increased from 41,29,09,200 to 41,29,95,978 equity shares, each with a face value of ₹1/-.

Business Update Positive

2026-06-02 17:39

- Mankind Lifesciences Pvt. Ltd. (WOS of Mankind Pharma) acquired the remaining 10% stake in Upakarma Ayurveda Pvt. Ltd. for ₹75 Lakhs. - Upakarma is now a 100% wholly-owned step-down subsidiary, engaged in Ayurvedic, herbal & nutraceutical products, with a FY26 turnover of ₹18.02 Cr. This aims for operational efficiencies.

Business Update Neutral

2026-05-27 16:17

Mankind Pharma Limited will participate in an Investor Conference organized by Bank of America on June 1, 2026, and meet with various investors on June 2, 2026, in Mumbai. The company confirmed that no unpublished price sensitive information would be disclosed during these interactions, with discussions based on the general business outlook and information already in the public domain.

Business Update Positive

2026-05-26 17:02

Management guided for double-digit top-line growth in FY27, aiming to outperform IQVIA. The FY27 EBITDA margin is projected to be 25.5-26.5%, an improvement over FY26 adjusted margin. Capex for FY27 is estimated at 6-7% of revenue, including ₹500 crores for a new Vadodara biotech facility. The effective tax rate will increase to 25-26% in FY27 due to the end of the Sikkim exemption. The company is on track to repay acquisition debt by FY28, targeting a net debt to adjusted EBITDA ratio of 0.5x for FY27. Growth drivers include acute portfolio normalization, chronic therapy momentum, specialty products (including GLP-1 pen launch), and high double-digit growth in international markets.

Business Update Neutral

2026-05-20 21:19

Mankind Pharma Limited announced that its management and officials will participate in investor meetings with various investors in Singapore on May 25-26, 2026. The company clarified that no unpublished price sensitive information will be disclosed, and discussions will focus on the general business outlook and information already in the public domain.

Business Update Neutral

2026-05-20 16:07

Mankind Pharma Limited has informed that the audio recording of the Investor Conference Call for Q4 & FY26, held on May 20, 2026, is now available on the company's website. This filing is in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is for investor reference.

Financials Positive

2026-05-19 20:10

Consolidated Revenue from Operations for Q4 FY26 increased to ₹3,443 Cr from ₹3,079 Cr (▲11.8% YoY). Adjusted EBITDA grew to ₹933 Cr from ₹711 Cr (▲31.1% YoY), and Net Profit (PAT) rose to ₹559 Cr from ₹429 Cr (▲30.4% YoY). Adjusted EBITDA Margin expanded to 27.1% from 23.1% (▲400bps) YoY.

Ownership Neutral

2026-05-19 19:41

Mankind Pharma Limited's Nomination and Remuneration Committee approved the allotment of 80,872 equity shares, face value ₹1/-, on May 19, 2026, to eligible employees under the ESOP Plan 2022. This allotment increases the paid-up share capital from 41,28,28,328 to 41,29,09,200 equity shares, which rank pari-passu with existing shares.

Financials Positive

2026-05-19 19:34

CRITICAL RED FLAG DETECTED

Standalone Revenue ₹2,581.82Cr vs ₹2,119.46Cr (▲21.80% YoY), EBITDA ₹896.02Cr vs ₹341.84Cr (▲162.15% YoY), PAT ₹713.61Cr vs ₹235.16Cr (▲203.46% YoY) for the quarter ended March 31, 2026. EBITDA Margin 34.70% vs 16.13% (▲1857bps). The Board also approved an additional investment of up to ₹500 Cr in Mankind Medicare Private Limited and noted the decision of Executive Directors to forgo commission for FY 2025-26 to strengthen cash position. Mr. Pramod Gokhale, Global Chief Information Officer, resigned.

Financials Positive

2026-05-19 19:29

CRITICAL RED FLAG DETECTED

Mankind Pharma reported strong consolidated results for Q4 FY26. Consolidated Revenue stood at ₹3,442.93 Cr vs ₹3,079.37 Cr (▲11.81% YoY), EBITDA at ₹909.71 Cr vs ₹685.51 Cr (▲32.70% YoY), and PAT at ₹559.42 Cr vs ₹428.99 Cr (▲30.40% YoY). EBITDA Margin expanded to 26.42% vs 22.26% (▲416bps). The Board also approved re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director, re-appointment of Cost Auditors, and an additional investment of up to ₹500 crores in Mankind Medicare Private Limited. Executive Directors decided not to draw commission for FY26 to strengthen cash position for business expansion.

Financials Positive

2026-05-19 19:28

Standalone Revenue ₹2,581.82Cr vs ₹2,119.46Cr (▲21.81% YoY), EBITDA ₹896.02Cr vs ₹341.84Cr (▲162.11% YoY), PAT ₹713.61Cr vs ₹235.16Cr (▲203.46% YoY). EBITDA Margin 34.70% vs 16.13% (▲1857bps).

Financials Neutral

2026-05-19 19:22

CRITICAL RED FLAG DETECTED

Mankind Pharma reported strong Q4 FY26 consolidated financial results. Revenue from operations increased to ₹3,442.93 Cr from ₹3,079.37 Cr (▲11.79% YoY). EBITDA rose to ₹1,044.17 Cr from ₹934.52 Cr (▲11.73% YoY), with EBITDA Margin at 30.33% compared to 30.35% (▼2bps). Net Profit (PAT) grew significantly to ₹559.42 Cr from ₹428.99 Cr (▲30.40% YoY). The board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director and noted the resignation of Mr. Pramod Gokhale, Global Chief Information Officer. Executive Directors also decided to forgo commission for FY26 to strengthen cash. Ongoing income tax proceedings are an 'Emphasis of Matter' in the auditor's report.

543904

Mankind Pharma Ltd

Price Chart

Filing History

Unlock Full History